The grant is worth $150,000, although venture capital firm Elevate Ventures added $50,000 alongside the Indiana Economic Development Corporation. The phase 1 grant also puts the now Indiana-based startup on the road to earning a larger development grant worth $750,000. Sintact developed an implantable film that helps prevent internal scar formation after a surgery.
“It’s exciting to get this kind of validation and support from an organization like the NSF SBIR program, not to mention the additional contribution from Elevate Ventures and the IEDC,” said Sintact CEO Erik Robinson in a statement. “These organizations have provided an incredible opportunity that will enable us to make substantial progress toward bringing our technology to market and ultimately improving patients’ lives.”
This grant will pay for a three-month animal study, a longer version of research done at the Ann & Robert H. Lurie Children’s Hospital of Chicago which reduced scar formation by 86 percent.
“It’s wonderful to see Sintact making such great progress since the program,” said Health Wildcatters CEO Hubert Zajicek. “They have all the elements for success, so it’s exciting to watch all those elements come together as they get closer to bringing their technology to the patients who can benefit from it.”0